Publication & Citation Trends
Publications
0 total
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma OA
Cited by 99
Semantic Scholar
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models OA
Cited by 51
Semantic Scholar
Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083). OA
Cited by 170
Semantic Scholar
Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis. OA
Cited by 365
Semantic Scholar
Pre-Clinical Activity of the Novel, First-in-Class p97 Inhibitor, CB-5083, in Multiple Myeloma
Cited by 1
Semantic Scholar
Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway OA
Cited by 74
Semantic Scholar
555 CB-5083, a first in class inhibitor of the AAA-ATPase p97/VCP, induces irresolvable ER stress that results in antitumor activity in solid and hematological tumor models
Cited by 0
Semantic Scholar
Abstract 951: CB-5083 is a novel first in class p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models
Cited by 1
Semantic Scholar
Research Topics
PI3K/AKT/mTOR signaling in cancer
(29)
Liver physiology and pathology
(16)
Cancer Mechanisms and Therapy
(16)
Lung Cancer Treatments and Mutations
(14)
HER2/EGFR in Cancer Research
(8)
Affiliations
Exelixis (United States)
Vanderbilt University
Aptose Biosciences (United States)
The University of Texas Medical Branch at Galveston